Skip to main content
Pulike Biological Engineering,Inc. logo

Pulike Biological Engineering,Inc. — Investor Relations & Filings

Ticker · 603566 ISIN · CNE1000025N0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,080 across all filing types
Latest filing 2025-08-28 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 603566

About Pulike Biological Engineering,Inc.

http://en.pulike.com.cn/

Pulike Biological Engineering, Inc. specializes in the research, development, and production of veterinary biological products and pharmaceutical preparations. The company focuses on animal disease prevention through the manufacture of high-end vaccines, diagnostic reagents, and veterinary medicines. Its product range primarily serves the swine and poultry sectors, featuring advanced biologicals such as genetically engineered vaccines and synthetic peptide products. Pulike maintains a strong emphasis on technological innovation, utilizing national-level research platforms to develop solutions for complex animal health challenges. The company’s core activities encompass the entire value chain from basic biotechnology research to the commercialization of veterinary health solutions, aiming to improve livestock productivity and biosecurity.

Recent filings

Filing Released Lang Actions
普莱柯2025年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2025 年半年度报告摘要' which translates to '2025 Semi-Annual Report Summary'. It contains detailed financial data for the half-year period ending June 30, 2025, including total assets, net profit, earnings per share, and shareholder information. The document explicitly states it is a summary of the half-year report and references the full report on the official stock exchange website. The length is 2721 characters, which is relatively short but contains substantive financial data and analysis, not just an announcement or a link. It is not a mere announcement or certification but includes key financial metrics and shareholder data typical of an Interim / Quarterly Report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2025-08-28 Chinese
普莱柯关于使用部分闲置自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 普莱柯生物工程股份有限公司 regarding the use of part of its idle funds for cash management. It details the purpose, amount, types of financial products involved (mainly large certificates of deposit), risk control measures, and the board approval process. There are no financial statements or detailed financial results presented. The document is a formal disclosure about a financing or capital management activity, specifically the use of idle funds for cash management products. This fits the category of Capital/Financing Update (CAP). The document length is short (2102 characters), and it is not a report publication announcement or a certification. Therefore, the best classification is CAP with high confidence.
2025-08-28 Chinese
华泰联合证券有限责任公司关于普莱柯生物工程股份有限公司使用部分闲置募集资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed opinion and verification report from Huatai United Securities regarding the use of idle raised funds by Pulike Bioengineering Co., Ltd. for cash management. It includes specifics about the raised funds, investment purpose, risk control measures, decision procedures, and the sponsor's opinion. The document is not a financial report like an annual or interim report, nor is it a brief announcement or voting result. It is a formal verification and audit opinion related to the use of raised funds, which aligns with the category of Audit Report / Information (AR). The document length is 3087 characters, which is sufficient for a detailed audit opinion but not a full annual or interim report. Therefore, the best classification is AR with high confidence.
2025-08-28 Chinese
普莱柯关于使用闲置募集资金进行现金管理到期赎回的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by 普莱柯生物工程股份有限公司 regarding the use of idle raised funds for cash management and the maturity redemption of such funds. It details the approval process by the board and shareholders, the amounts involved, types of financial products used, and the redemption status. The document is an announcement about the company's capital management activities, specifically the use of idle raised funds for cash management and their redemption. It does not contain comprehensive financial statements or detailed financial performance data, nor is it a report or presentation. It is an update on financing activities related to capital usage. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is short (1548 characters), but it contains substantive information about capital usage, not just a notice of report publication or certification, so it is not RPA or RNS.
2025-08-22 Chinese
普莱柯关于获得新兽药注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by 普莱柯生物工程股份有限公司 regarding the approval and registration of a new veterinary drug (新兽药注册证书) by the Ministry of Agriculture and Rural Affairs of China. It details the new drug's name, classification, components, usage, development background, and expected impact on the company. The document is short (1219 characters) and serves as an official announcement of a regulatory approval rather than a financial report or detailed management discussion. It does not contain financial data, earnings, or management changes. It is not a report publication announcement since it is not about releasing a report but about announcing a regulatory approval. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2025-07-18 Chinese
普莱柯2025年半年度业绩预告
Earnings Release Classification · 95% confidence The document is a performance forecast for the half-year period ending June 30, 2025, providing preliminary estimated net profit figures and growth percentages compared to the previous year. It explicitly states that the data is preliminary and unaudited, and that the final accurate financial data will be disclosed in the formal half-year report. The document is short (1274 characters) and serves as an announcement of expected financial results rather than a comprehensive financial report containing actual financial statements or detailed analysis. Therefore, it fits the category of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results highlighting key figures and expectations.
2025-07-11 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.